The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | Game-changing drugs for amyloidosis treatment
There are two primary routes of therapy for amyloidosis: treating the underlying plasma cell dyscrasia, and clearing amyloid deposits. In this insightful interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, gives an overview of some of the most exciting data in the field, including bortezomib combinations, single agent daratumumab, and ixazomib, which have shown great potential. Dr Wechalekar highlights ongoing studies of monoclonal antibodies that act through clearing amyloid deposits, including a highly anticipated anti-SAP antibody being developed (NCT03044353), and birtamimab (NEOD001), currently being investigated in the Phase III VITAL study (NCT02312206).
